	US 12,234,455 B2
	Therapeutic oligonucleotides
Fabrizio d′Adda di Fagagna, Milan (IT); Francesca Rossiello, Milan (IT); Julio Aguado, Milan (IT); and Corey Jones-Weinert, Milan (IT)
Assigned to IFOM—FONDAZIONE ISTITUTO FIRC DI ONCOLOGIA MOLECOLARE, Milan (IT)
Filed by IFOM—FONDAZIONE ISTITUTO FIRC DI ONCOLOGIA MOLECOLARE, Milan (IT)
Filed on Oct. 7, 2020, as Appl. No. 17/065,409.
Application 17/065,409 is a continuation of application No. 15/748,133, abandoned, previously published as PCT/EP2016/068162, filed on Jul. 29, 2016.
Claims priority of application No. 15178809 (EP), filed on Jul. 29, 2015.
Prior Publication US 2021/0087567 A1, Mar. 25, 2021
Int. Cl. C07H 21/02 (2006.01); C07H 21/04 (2006.01); C12N 15/113 (2010.01)

CPC C12N 15/113 (2013.01) [C12N 2310/113 (2013.01); C12N 2310/314 (2013.01); C12N 2310/315 (2013.01); C12N 2310/321 (2013.01); C12N 2310/3231 (2013.01); C12N 2310/3233 (2013.01); C12N 2310/341 (2013.01); C12N 2310/3521 (2013.01); C12N 2310/3525 (2013.01)]

12 Claims

1. A method for treating a cancer in which a tumor maintains telomere length by an alternative lengthening of telomeres (ALT) mechanism in a subject in need of thereof, the method comprising:

administering to the subject, an oligonucleotide that is 6-25 nucleotides long and comprises one of the following sequences: (TTAGGG) SEQ ID No. 1, (TAGGGT) SEQ ID No. 2, (AGGGTT) SEQ ID No. 3, (GGGTTA) SEQ ID No. 4, (GGTTAG) SEQ ID No. 5 or (GTTAGG) SEQ ID No. 6 or a complementary sequence thereof or a variant or a mixture thereof, or

administering to the subject an oligonucleotide comprising one of the following sequences: (TTAGGG)n, (TAGGGT)n, (AGGGTT)n, (GGGTTA)n, (GGTTAG)n or (GTTAGG)n wherein 1<n<5,

wherein the variant comprises one of the following sequences: TCAGGG, TTCGGG, GTAGGG, TGAGGG, TTGGGG, TAAGGG, ATAGGG, CTAGGG, TTTGGG or TTAAGGG, and

wherein the cancer is selected from the group consisting of: soft tissue sarcoma, central nervous system cancer, urinary bladder cancer, adrenal gland or peripheral nervous system cancer, neuroendocrine neoplasms, kidney cancer, lung and pleural cancer, skin cancer, liver cancer, testis cancer, breast cancer, uterus cancer, ovary cancer, gall bladder cancer, oesophagus cancer and osteosarcoma.